PERSONALIZED MEDICINE IN BRONCHIAL OBSTRUCTION SYNDROME


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Bronchial obstruction syndrome (BOS) is mainly caused by asthma, obstructive pulmonary disease (COPD), or emphysema. Asthma and COPD can be effectively treated by bronchodilator therapies delivered by inhalation. Inhalation of beta2-adrenergic agonist and combination of the anticholinergic agent and the beta2-adrenergic agonist is advantageous for the treatment of any bronchoobstructive syndrome prevention and exacerbation of asthma and COPD.

Full Text

Restricted Access

About the authors

N. Berdnikova

I.M. Sechenov First Moscow State Medical University

Email: berdnad@mail.ru
PhD

M. Zhuravleva

I.M. Sechenov First Moscow State Medical University

MD

V. Kukes

I.M. Sechenov First Moscow State Medical University

MD, Academician of Russian Academy of Science

References

  1. Шмелев Е.И. Бронхообструктивный синдром - универсальное патологическое состояние в пульмонологии // Медицина неотложных состояний. - 2006; 5 (6): 8-13. URL http://www.mif-ua.com/
  2. Чучалин А.Г. Хронические обструктивные болезни легких / СПб: Невский диалект, 1998; с. 234-40, 436-40.
  3. Global Initiative for asthma (GINA), update 2014. URL http://www.ginasthma.org
  4. Global Initiative for COPD, update 2014. URL http://www.goldcopd.org/guidelines-resources.htm
  5. Holland A., Smith F., Penny K. et al. Metered dose inhalers versus nebulizers for aerosol bronchodilator delivery for adult patients receiving mechanical ventilation in critical care units (Review) // The Cochrane Collaboration and published in The Cochrane Library. - 2013; Issue 6. http://www.update-software.com/
  6. Green S., Turki J., Vegarno P. et al. Influencce of β2-adrenergic receptor genotypes on signal transduction in human airways smooth muscle cells // Am. J. Respir. Cell Mol. Biol. - 1995; 13: 25-33.
  7. Metzger N., Kockler D., Gravatt L. Confirmed beta16Arg/Arg polymorphism in a patient with uncontrolled asthma // Ann. Pharmacother. - 2008; 42 (6): 874-81.
  8. Ligett S. Pharmacogenetics or β1 and β2-adrenergic receptors // Pharmacology. - 2002; 137: 1213-6.
  9. Bleecker E., Posthma D., Lawrance R. et al. Effect of ADRB2 polymorphism on responce to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomized studies // Lancet. - 2007; 370: 2118-25.
  10. Генетика бронхолегочных заболеваний. Под ред. В.П. Пузырева, Л.М. Огородовой / М.: Атмосфера, 2010; с. 78-95.
  11. Tse S., Tantisira K., Weiss S. The Pharmacogenetics and Pharmacogenomics of Asthma Therapy // Pharmacogenomics J. - 2011; 11 (6): 383-92.
  12. Westby M. Anticholinergic agents for chronic asthma in adults // Cochrane Database Syst. Rev. - 2004; 3 (Art No CD003269).
  13. Carstairs J., Nimmo A., Barnes P. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung // Am. Rev. Respir. Dis. - 1985; 132 (3): 541-7.
  14. Бронхиальная астма. Под ред. акад. РАМН А.Г. Чучалина. В 2-х т. / М.: Агар, 1997; Т. 2.: с. 269-91, 303-21.
  15. Tatsuya Haga. Molecular properties of muscarinic acetylcholine receptors // Proc. Jpn. Acad. Ser. Phys. Biol. Sci. - 2013; 89 (6): http://www.ncbi.nlm.nih.gov/pmc/issues/226608/11PMC3749793
  16. Mak J., Barnes P. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung // Am. Rev. Respir. Dis. - 1990; 141 (6): 1559-68.
  17. Клиническая фармакология. Под ред. акад. РАН, проф. В.Г. Кукеса / М.: ГЭОТАР-Медиа, 2015; с. 526-47.
  18. Зырянов С.К., Айсанов З.Р. Воспроизведенные ингаляционные лекарственные средства: как оценить их свойства? // Пульмонология. - 2012; 3: http://journal.pulmonology.ru/index.php/pulm/article/viewFile/92/91
  19. Fuglsang A. The US and EU regulatory landscapes for locally acting generic/hybrid inhalation products intended for treatment of asthma and COPD // J. Aerosol. Med. Pulm. Drug. Deliv. - 2012; 25 (4): 243-7.
  20. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic, equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents http://www.ema.europa.eu/
  21. Зырянов С.К., Галеева Ж.А., Белоусов Ю.Б. Качественные генерики для лечения бронхообструктивных заболеваний: свет в конце тоннеля есть! // Лечащий врач. - 2014; 11: http://http://www.lvrach.ru/

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Russkiy Vrach Publishing House